Dataset opportunity
Medrhythms — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Medrhythms, usable for Diagnostic AI and Computer Vision.
Score
66.4
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market
Global AI in Medical Imaging market = $1.88 billion in 2025, projected to reach $29.95 billion by 2034, CAGR 36.91% (source: Fortune Business Insights)
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-06-04
Can surgical robots fly? SS Innovations discusses challenges, solutions
therobotreport.com ↗ - 📰press2026-06-04
More Americans own wearables, connected health devices: survey
medtechdive.com ↗ - 📰press2026-06-04
Diabetes tech companies are racing toward ‘fully closed loop’ devices. But automation comes with trade-offs.
medtechdive.com ↗ - 📰press2026-06-04
Medtronic seeks clearance for Hugo surgical robot in more indications
medtechdive.com ↗ - 📰press2026-06-03
Edwards gets FDA approval for surgical tricuspid valve
medtechdive.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Medrhythms possesses a substantial Medical Imaging Dataset, primarily consisting of Image modality data, complemented by data volume metrics, IoT data, and comprehensive medical records. This rich and diverse dataset is exceptionally well-suited for training and validating Diagnostic AI models, enabling the development of advanced algorithms for disease detection, segmentation, and computer-assisted diagnosis.
This type of data is highly valuable due to the high demand from AI developers and its rarity in high-quality, annotated forms, driving a rapidly expanding market. The global AI in medical imaging market, valued at $1.88 billion in 2025, is projected to reach $29.95 billion by 2034, exhibiting a 36.91% CAGR during this period. Despite the complexities of managing Protected Health Information (PHI), adhering to HIPAA and other privacy regulations, and requiring patient consent for identifiable data, the data's potential for de-identification or aggregation for commercial use makes it a critical asset for advancing healthcare AI. ⚠ Diligence (valuable data, access to negotiate): Data contains Protected Health Information (PHI) and is subject to HIPAA and other privacy regulations.; Data is generated from regulated medical devices/digital therapeutics.; Patient consent for data sharing is required for personally identifiable information.; Data is often de-identified or aggregated for commercial use. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This opportunity presents access to Medrhythms' proprietary and multimodal dataset, anchored by medical imaging and rich real-time gait data. This unique combination is highly valuable for Diagnostic AI and medical-AI companies seeking to develop advanced solutions for movement disorders. With the global AI in Medical Imaging market projected to reach nearly $30 billion by 2034, this dataset offers a critical foundation for innovation in a rapidly expanding sector.
See dimension details ↓- Dataset Specificity78
dominant 'medical_records', sector healthcare, 2 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume68
3 evidence hits, explicit data-volume mention
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
The AI in Medical Imaging Market is projected to grow from USD 1.65 billion in 2025 to USD 8.23 billion by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 30.7%, indicating very high and increasing demand for medical imaging datase
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation22
0 data-appetite signals (0 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 5 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit58
⚠ review — MedRhythms is a digital therapeutics company that develops and sells medical devices and software, and while they generate proprietary data as a by-product, their terms of service indicate they may sell aggregated or anonymized data, making them an unsuitable target for dormant data opportunities. Issues: MedRhythms' Terms of Service explicitly state that the company may analyze and process user data to create aggregated or anonymized statistics or data, and may
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
IoT / sensor data
This evidence confirms the collection of real-time gait data via sensor-based platforms, processed through proprietary clinical algorithms, offering crucial time series data for AI models in movement analysis.
Medical records / imaging
This indicates the availability of medical imaging data, specifically gathered during studies focused on gait characteristics and participant quality of life, highly sought after by diagnostic-imaging companies for AI development.
Data-volume signal
This highlights the dataset's multimodal nature and demonstrates real-world user engagement and clinical efficacy, providing robust performance metrics for validating AI models in digital health.
Coverage
Scanned sources
Deliverable
Premium dataset report
Medrhythms Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market = $1.88 billion in 2025, projected to reach $29.95 billion by 2034, CAGR 36.91% (source: Fortune Business Insights). Investment score 66.4/100 (confidence 0.49). Recommended action: Data Sharing Agreement.